Beam Therapeutics Inc
BEAM
NASDAQ
Biotechnology
$26.75
USD
+0.24 (+0.91%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $2.73B
Volume 1.2M
Revenue
$164.01M
TTM
+158.0%
YoY
Gross Margin
100%
TTM
0.0%
YoY
Net Income
$-65.04M
TTM
+83.2%
YoY
Operating Cash Flow
$-369.73M
TTM
-5.2%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
Revenue | 7.5 | 8.5 | 9.7 | 114.1 | 31.7 |
YoY Growth | +0.8% | -28.1% | -32.0% | +279.5% | +324.9% |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 7.5 | 8.5 | 9.7 | 114.1 | 31.7 |
Selling, General & Administrative | 27.9 | 26.9 | 26.7 | 32.3 | 34.4 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 126.8 | 128.6 | 136.5 | 131.6 | 139.0 |
Operating Income | -119.3 | -120.2 | -126.8 | -17.4 | -107.2 |
EBITDA | -113.8 | -114.6 | -121.3 | -11.8 | -101.6 |
Other Income / Expense | 1.1 | 5.5 | 3.2 | 251.1 | 3.0 |
Total Other Income / Expense | 11.0 | 17.9 | 14.1 | 261.7 | 12.9 |
Income Before Income Taxes | -108.3 | -102.3 | -112.7 | 244.3 | -94.3 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -108.3 | -102.3 | -112.7 | 244.3 | -94.3 |
Consolidated Net Income / Loss | -108.3 | -102.3 | -112.7 | 244.3 | -94.3 |
Net Income Attributable to Common Shareholders | -108.3 | -102.3 | -112.7 | 244.3 | -94.3 |
Basic EPS | -$1.23 | -$1.00 | -$1.10 | $2.37 | -$0.91 |
Diluted EPS | -$1.23 | -$1.00 | -$1.10 | $2.37 | -$0.91 |
Basic Shares Outstanding | 88.0M | 102.0M | 102.6M | 103.1M | 103.3M |
Diluted Shares Outstanding | 88.0M | 102.0M | 102.6M | 103.1M | 103.3M |